EX-FILING FEES 2 d526882dexfilingfees.htm EX-FILING FEES EX-FILING FEES

Exhibit 107

Calculation of Filing Fee Tables

424(b)(5)

(Form Type)

Madrigal Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

 

      Security
Type
  

Security

Class Title

  

Fee

Calculation

or Carry
Forward

Rule

  

Amount

Registered

  

Proposed

Maximum

Offering

Price

Per Unit

  

Maximum

Aggregate

Offering

Price

  

Fee

Rate

  

Amount of

Registration

Fee (1)

Newly Registered Securities

Fees to Be

Paid

  

Equity

  

Common Stock, $0.0001 par

value per share

  

Rule 457(r)

  

3,790,625 (2)

  

$151.69

  

$574,999,702

  

0.00014760

  

$84,870

Fees to Be

Paid

  

Equity

  

Pre-funded warrants to purchase

common stock

  

Rule 457(r)

  

2,048,098

  

$151.69 (3)

  

(3)

  

0.00014760

  

(3)

Fees Previously Paid

  

N/A

  

N/A

  

N/A

  

N/A

  

N/A

  

N/A

       

N/A

Carry Forward Securities

Carry Forward Securities

  

N/A

  

N/A

  

N/A

  

N/A

       

N/A

         
     Total Offering Amounts         

$574,999,702

       

$84,870

     Total Fees Previously Paid                   

     Total Fee Offsets                   

     Net Fee Due                   

$84,870

 

(1)

Calculated in accordance with Rule 457(r) under the Securities Act of 1933, as amended (the “Securities Act”). In accordance with Rules 456(b) and 457(r) under the Securities Act the registrant initially deferred payment of all of the registration fees for the Registration Statement on Form S-3 (Registration No. 333-256666), filed on June 1, 2021.

(2)

Includes 494,429 shares of common stock that the underwriters have an option to purchase and 2,048,098 shares of common stock that are issuable upon exercise of the pre-funded warrants referenced below.

(3)

Represents the sum of the pre-funded warrants sales price of $151.6899 per pre-funded warrant and the exercise price of $0.0001 per share issuable pursuant to the pre-funded warrants. Pursuant to Securities and Exchange Commission staff interpretation, the entire fee is allocated to the common stock underlying the pre-funded warrants.